Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Group 1 - The company is restructuring its Human Health business in anticipation of the expiration of patent protection for its major drug, Keytruda, in two years [1] - This strategic move aims to enhance operational efficiency and focus on core areas of growth within the pharmaceutical sector [1] - The decision reflects a proactive approach to mitigate potential revenue impacts from the loss of exclusivity on Keytruda, which has been a significant revenue driver [1] Group 2 - Keytruda is recognized as a blockbuster treatment, indicating its substantial market success and revenue generation capabilities [1] - The impending patent expiration poses a challenge, as generic competition may enter the market, affecting sales [1] - The restructuring may also involve exploring new therapeutic areas or partnerships to sustain growth post-Keytruda [1]